Ribavarin: Difference between revisions
| Line 27: | Line 27: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hemolytic anemia, TTP | *[[Hemolytic anemia]], [[TTP]] | ||
*Bacterial disease | *[[Bacterial disease]] | ||
*Hepatotoxicity | *[[Hepatotoxicity]] | ||
*MI | *[[MI]] | ||
*Suicide | *[[Suicide]] | ||
===Common=== | ===Common=== | ||
*Neutropenia | *[[Neutropenia]] | ||
*Nausea, vomiting, diarrhea | *[[Nausea]], [[vomiting]], [[diarrhea]] | ||
*Asthenia, dizziness, fatigue | *Asthenia, [[dizziness]], [[fatigue]] | ||
*Weight loss | *Weight loss | ||
*Pruritus | *[[Pruritus]] | ||
==Pharmacology== | ==Pharmacology== | ||
Revision as of 17:58, 29 September 2016
Administration
- Type: Antiviral- FDA approved for Hepatitis C, severe RSV infection. Off-label use: herpes simplex, influenza, viral hemorrhagic fever
- Dosage Forms: 200 tab, 200 cap
- Routes of Administration: Oral, inhalation
- Common Trade Names: Copegus, Rebetol, Ribasphere
Adult Dosing
- 200-1000mg daily (dose depends on genotype and concurrent treatment with interferon)
Pediatric Dosing
- Hep C: >2 years old: 15mg/kg daily OR 400-1200mg daily
- RSV (severe cases): 20mg/ml aerosolized over 12-18 hours x 3-7 days
Special Populations
- Pregnancy Rating: X
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: reduced doses for mild-moderate impairment, do not use if CrCl <50
Contraindications
- Allergy to class/drug
- Autoimmune hepatitis
- Coadministration with didanosine
- Hemoglobinopathy (e.g. thalassemia, sickle cell)
- Pregnant or potentially pregnant women, men who may impregnate someone
- Renal impairment (CrCl <50)
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: ~300 hours
- Metabolism:
- Excretion: Mostly renal
Mechanism of Action
- Mechanism not well understood